Bevacizumab 400mg
| Product Overview | |
| Generic Name | Bevacizumab 400mg |
| Brand Name(s) | Avastin, Bevatas |
| Form | IV Injection Vial |
| Strength | 400 mg/16 mL |
| Therapeutic Class | anti-angiogenic |
| ATC Code | L01FG01 |
| Manufacturing & Regulatory | |
| Manufacturer | Roche, Intas |
| Country | India/USA/EU |
| GMP Compliance | FDA/EMA/WHO-GMP |
| DMF/CEP | Type II |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 Vials |
| Shelf Life | 24 months |
| Storage | 2–8 °C, protect from light |
| Incoterms | Ex-works Mex |
| Lead Time | 7 - 10 days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | Upon Request |
Description
Indications/Usage: Cancer (colorectal, lung, breast, ovarian, RCC)
Cofepris approvals to Zydus Lifesciences Ltd (Bevacizumab biosimilar (Bhava)
